# OnCo record kras-inhibitors (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/kras-inhibitors/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "kras-inhibitors" ;
  schema:name "KRAS & RAS inhibitors"@en ;
  schema:description "Drugs against the most common cancer gene, considered impossible to target until sotorasib in 2021."@en ;
  schema:url <https://onco.cc/technologies/kras-inhibitors/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/KRAS> ;
  owl:sameAs <http://www.wikidata.org/entity/Q20969980> ;
  schema:citation <https://en.wikipedia.org/wiki/KRAS> ;
  onco:status "approved" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/pancreatic/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:targets <https://onco.cc/targets/kras/>, <https://onco.cc/targets/egfr/> ;
  onco:drugs <https://onco.cc/drugs/sotorasib/>, <https://onco.cc/drugs/adagrasib/>, <https://onco.cc/drugs/daraxonrasib/> ;
  onco:companies <https://onco.cc/companies/amgen/>, <https://onco.cc/companies/bms/>, <https://onco.cc/companies/revolution-medicines/>, <https://onco.cc/companies/bridgebio-oncology-therapeutics/>, <https://onco.cc/companies/erasca/>, <https://onco.cc/companies/kumquat-biosciences/>, <https://onco.cc/companies/treeline-biosciences/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-codebreak-100-sotorasib-kras-g12c-pancreatic-nejm-2023/>, <https://onco.cc/key-papers/paper-krystal-1-adagrasib-kras-g12c-solid-tumours-jco-2023/>, <https://onco.cc/key-papers/paper-daraxonrasib-pancreatic-n-engl-j-med-2026/>, <https://onco.cc/key-papers/paper-bournet-kras-g12d-prognosis-pancreatic-ctg-2016/> .